- Home
- USAU vs ZNTL Comparison
USAU vs ZNTL Comparison
Compare USAU & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- ZNTL
- Stock Information
- Founded
- USAU 2014
- ZNTL 2014
- Country
- USAU United States
- ZNTL United States
- Employees
- USAU N/A
- ZNTL N/A
- Industry
- USAU Precious Metals
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- USAU Basic Materials
- ZNTL Health Care
- Exchange
- USAU Nasdaq
- ZNTL Nasdaq
- Market Cap
- USAU 126.8M
- ZNTL 105.8M
- IPO Year
- USAU N/A
- ZNTL 2020
- Fundamental
- Price
- USAU $15.21
- ZNTL $1.56
- Analyst Decision
- USAU Strong Buy
- ZNTL Buy
- Analyst Count
- USAU 2
- ZNTL 7
- Target Price
- USAU $17.00
- ZNTL $8.46
- AVG Volume (30 Days)
- USAU 299.9K
- ZNTL 831.8K
- Earning Date
- USAU 09-12-2025
- ZNTL 11-11-2025
- Dividend Yield
- USAU N/A
- ZNTL N/A
- EPS Growth
- USAU N/A
- ZNTL N/A
- EPS
- USAU N/A
- ZNTL N/A
- Revenue
- USAU N/A
- ZNTL $26,865,000.00
- Revenue This Year
- USAU N/A
- ZNTL N/A
- Revenue Next Year
- USAU N/A
- ZNTL N/A
- P/E Ratio
- USAU N/A
- ZNTL N/A
- Revenue Growth
- USAU N/A
- ZNTL N/A
- 52 Week Low
- USAU $5.11
- ZNTL $1.01
- 52 Week High
- USAU $15.61
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- USAU 70.72
- ZNTL 46.67
- Support Level
- USAU $12.47
- ZNTL $1.60
- Resistance Level
- USAU $13.19
- ZNTL $2.02
- Average True Range (ATR)
- USAU 0.77
- ZNTL 0.14
- MACD
- USAU 0.20
- ZNTL -0.04
- Stochastic Oscillator
- USAU 90.54
- ZNTL 16.95
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.